CNGnome NGS Array - A new gold standard for CNV detection

For over a decade, chromosomal microarray (CMA) has been the go-to genetic test for children with congenital anomalies, intellectual delay, developmental delay, and autism. Despite technical advancements, CMA still faces limitations in probe location and number, which can lead to missed copy number variants (CNVs) and difficulties in pinpointing breakpoints.

Enter the CNGnome NGS Array. Utilizing a next-generation sequencing (NGS)-based whole-genome sequencing (WGS) approach, this innovative technology offers higher resolution, increased coverage, precision and accuracy in CNV detection. By eliminating the need for probes, the CNGnome NGS Array enhances diagnostic yield, streamlines the diagnostic process, and ultimately helps improve patient care.

Join us for an insightful webinar, where we delve into case studies and the technical prowess of CNGnome NGS Array testing. Discover how this cutting-edge technology is poised to replace traditional array-based CMA in assessing genetic disease etiologies. As a leader in genomic research, we provide in-depth insights into the transformative potential of a whole-genome approach to CNV detection.

Don’t miss this opportunity to explore the future of genetic diagnostics and the groundbreaking capabilities of the CNGnome NGS Array. Together, let’s navigate the complexities of our genetic code and unlock new possibilities in patient care.

This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.